Patent intelligence · WO
WO 2021005493
ANTAGONISTES DU CGRP ET TOXINES BOTULINIQUES POUR LE TRAITEMENT DE TROUBLES INFLAMMATOIRES ET NEUROLOGIQUES
ANTAGONISTES DU CGRP ET TOXINES BOTULINIQUES POUR LE TRAITEMENT DE TROUBLES INFLAMMATOIRES ET NEUROLOGIQUES
Patent details — WO 2021005493
- Jurisdiction
- WO
- Status
- granted
- Grant date
- Jan 14, 2021
- Expiration
- Jan 9, 2041
- Applicant
- ALLERGAN PHARMACEUTICALS INT LTD [IE]
- CPC classes
- A61K 38/ 48 A I, A61K 45/ 06 A I, A61K/384893, A61K/393955
Quick answer
WO 2021005493 (ANTAGONISTES DU CGRP ET TOXINES BOTULINIQUES POUR LE TRAITEMENT DE TROUBLES INFLAMMATOIRES ET NEUROLOGIQUES) is held by ALLERGAN PHARMACEUTICALS INT LTD [IE]. Status: granted. Granted Jan 14, 2021. Expires Jan 9, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ALLERGAN PHARMACEUTICALS INT LTD [IE]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 38/ 48 A I, A61K 45/ 06 A I, A61K/384893, A61K/393955, A61K/4506, A61P 25/ 00 A I
More from ALLERGAN PHARMACEUTICALS INT LTD [IE]
Related pharmaceutical patents in our USPTO index.
-
US 12383545
TREATMENT OF MIGRAINE
granted -
US 2025064788
TREATMENT OF MIGRAINE
granted -
US 2024180883
TREATMENT OF MIGRAINE
granted -
WO 2024081718
ANTAGONISTE DU RÉCEPTEUR CGRP POUR LE TRAITEMENT DE LA MIGRAINE
granted -
CA 3244873
TRAITEMENT PRÉVENTIF DE LA MIGRAINE
granted -
WO 2023077094
TRAITEMENT D'UN TROUBLE DÉPRESSIF MAJEUR
granted -
US 2023130736
METHODS OF TREATING MIGRAINE
granted -
US 2022380379
PHARMACEUTICAL COMPOUNDS
granted
Frequently asked questions
What is US patent 2021005493?
WO 2021005493 (ANTAGONISTES DU CGRP ET TOXINES BOTULINIQUES POUR LE TRAITEMENT DE TROUBLES INFLAMMATOIRES ET NEUROLOGIQUES) is held by ALLERGAN PHARMACEUTICALS INT LTD [IE]. Status: granted. Granted Jan 14, 2021. Expires Jan 9, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns WO 2021005493?
ALLERGAN PHARMACEUTICALS INT LTD [IE] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does WO 2021005493 expire?
Our index shows an expiration date of Jan 9, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.